These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 14999615

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.
    Shen X, Lagergård T, Yang Y, Lindblad M, Fredriksson M, Holmgren J.
    Infect Immun; 2001 Jan; 69(1):297-306. PubMed ID: 11119518
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Maternal group B streptococcal immunization: capsular polysaccharide (CPS)-based vaccines and their implications on prevention.
    Palmeiro JK, De Carvalho NS, Botelho AC, Fracalanzza SE, Madeira HM, Dalla-Costa LM.
    Vaccine; 2011 May 12; 29(21):3729-30. PubMed ID: 21414381
    [Abstract] [Full Text] [Related]

  • 26. Quantitative determination of antibodies to type III group B streptococcal polysaccharide.
    Guttormsen HK, Baker CJ, Edwards MS, Paoletti LC, Kasper DL.
    J Infect Dis; 1996 Jan 12; 173(1):142-50. PubMed ID: 8537651
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice.
    Paoletti LC, Pinel J, Rodewald AK, Kasper DL.
    J Infect Dis; 1997 May 12; 175(5):1237-9. PubMed ID: 9129094
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
    Madhi SA, Cutland CL, Jose L, Koen A, Govender N, Wittke F, Olugbosi M, Meulen AS, Baker S, Dull PM, Narasimhan V, Slobod K.
    Lancet Infect Dis; 2016 Aug 12; 16(8):923-34. PubMed ID: 27139805
    [Abstract] [Full Text] [Related]

  • 32. Conjugation of β-glucan markedly increase the immunogencity of meningococcal group Y polysaccharide conjugate vaccine.
    Qiao W, Ji S, Zhao Y, Hu T.
    Vaccine; 2015 Apr 21; 33(17):2066-72. PubMed ID: 25728319
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14.
    Guttormsen HK, Baker CJ, Nahm MH, Paoletti LC, Zughaier SM, Edwards MS, Kasper DL.
    Infect Immun; 2002 Apr 21; 70(4):1724-38. PubMed ID: 11895934
    [Abstract] [Full Text] [Related]

  • 36. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.
    Wessels MR, Paoletti LC, Rodewald AK, Michon F, DiFabio J, Jennings HJ, Kasper DL.
    Infect Immun; 1993 Nov 21; 61(11):4760-6. PubMed ID: 8406875
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.